3SBio Inc (1530) - Financial and Strategic SWOT Analysis Review

3SBio Inc (1530) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description - A detailed description of the company’s operations and business divisions.
• Corporate strategy - Analyst’s summarization of the company’s business strategy.
• SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history - Progression of key events associated with the company.
• Major products and services - A list of major products, services and brands of the company.
• Key competitors - A list of key competitors to the company.
• Key employees - A list of the key executives of the company.
• Executive biographies - A brief summary of the executives’ employment history.
• Key operational heads - A list of personnel heading key departments/functions.
• Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

3SBio Inc (3SBio) is a biotechnology company that discovers, develops, manufactures, and markets biopharmaceutical products. Its major products include TPIAO for the treatment of chemotherapy-induced Thrombocytopenia (CIT), ITP, and pediatric ITP; EPIAO to treat anemia associated with CKD, treatment of chemotherapy-induced anemia (CIA), and the reduction of allogeneic blood transfusion in surgery patients; Yisaipu to treat ankylosing spondylitis (AS) and psoriasis; Cipterbin to treat HER2-positive metastatic breast cancer in combination with chemotherapy; Mandi to treat androgenetic alopecia (AGA) and alopecia areata; and Remitch to treat hemodialysis pruritus. The company also offers contract development and manufacturing operations through its subsidiaries. 3SBio provides its products to hospitals and medical institutions. The company operates manufacturing bases in China and Italy. 3SBio is headquartered in Shenyang, Liaoning, China.

3SBio Inc Key Recent Developments

• Aug 29, 2025: 3SBio Announces 2025 Interim Results: Value Realization of Innovative Achievements and Strong Long-Term Growth Momentum
• Aug 29, 2025: 3SBio : Interim Results Announcement for the Six Months Ended 30 June 2025
• Jul 25, 2025: Pfizer and 3SBio conclude licensing deal for SSGJ-707
• May 20, 2025: Pfizer signs global licensing deal with 3SBio for bispecific antibody

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company